MINIRIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MINIRIN (MINIRIN).
Desmopressin is a synthetic analog of antidiuretic hormone (ADH) that increases water reabsorption in the renal collecting ducts by binding to V2 receptors, leading to increased aquaporin-2 expression and reduced urine output.
| Metabolism | Primarily metabolized in the liver; CYP450 enzymes not significantly involved. |
| Excretion | Renal (primarily as unchanged drug via glomerular filtration and tubular secretion; ~65% of an intravenous dose excreted unchanged in urine within 24 hours); fecal (~5–10% of an oral dose); minimal biliary elimination. |
| Half-life | Terminal elimination half-life: 2–3 hours (intravenous, subcutaneous); 3–5 hours (oral). Clinical context: Short half-life necessitates frequent dosing; duration of antidiuretic effect may outlast plasma levels due to receptor binding. |
| Protein binding | Approximately 1% bound to plasma proteins (negligible binding; primarily to albumin). |
| Volume of Distribution | 0.2–0.3 L/kg. Clinical meaning: Low Vd indicates limited extravascular distribution; mostly confined to extracellular fluid. |
| Bioavailability | Oral: 0.1–0.5% (low due to enzymatic degradation in GI tract and extensive first-pass metabolism); Subcutaneous: ~85–90%; Intranasal: ~3–5% (variable due to nasal absorption and metabolism). |
| Onset of Action | Intravenous: 15–30 minutes; Subcutaneous: 30–60 minutes; Oral: 1–2 hours; Intranasal: 30–60 minutes. Onset refers to initial antidiuretic effect. |
| Duration of Action | Intravenous: 6–12 hours; Subcutaneous: 6–12 hours; Oral: 6–12 hours; Intranasal: 8–12 hours. Clinical notes: Duration is dose-dependent; in central diabetes insipidus, dosing interval typically 8–12 hours. |
Adults: 1-2 sprays intranasally (10 mcg each) once daily; for diabetes insipidus, 1-2 sprays once or twice daily. Oral: 0.1-0.2 mg three times daily.
| Dosage form | SPRAY, METERED |
| Renal impairment | GFR >50 mL/min: No adjustment. GFR 10-50 mL/min: Caution, reduce dose by 50% or extend interval. GFR <10 mL/min: Contraindicated or avoid use. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Avoid use. |
| Pediatric use | Intranasal: Infants and children, 5 mcg (0.5 spray) once daily, titrate to effect. Oral: 0.05-0.1 mg three times daily, weight-based (0.1-1 mcg/kg) but not established. |
| Geriatric use | Initiate at lowest effective dose; monitor for hyponatremia and fluid retention; adjust based on renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for MINIRIN (MINIRIN).
| Breastfeeding | Desmopressin is excreted into breast milk in very small amounts; M/P ratio is approximately 0.3. It is generally considered compatible with breastfeeding. Because it is a peptide, oral bioavailability in the infant is low. Monitor infant for signs of water retention or electrolyte imbalance, though risk is minimal. |
| Teratogenic Risk | Desmopressin (MINIRIN) is classified as FDA Pregnancy Category B. No teratogenic effects have been observed in animal studies. In humans, limited data show no increased risk of major birth defects. However, due to antidiuretic effects, monitor for hyponatremia and fluid overload during pregnancy, particularly in third trimester when plasma volume increases. |
■ FDA Black Box Warning
No FDA black box warning.
| Common Effects | Headache Nausea Stomach pain |
| Serious Effects |
["Hypersensitivity to desmopressin or components","Moderate to severe renal impairment (CrCl <50 mL/min)","Hyponatremia or history of hyponatremia","Primary nocturnal enuresis in patients with polydipsia or fluid imbalance"]
| Precautions | ["Fluid restriction required to prevent water intoxication and hyponatremia","Monitor serum sodium in at-risk patients (e.g., elderly, cystic fibrosis)","Use with caution in patients with hypertension, coronary artery disease, or renal impairment","Allergic reactions possible"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum sodium, urine output, and fluid balance to prevent hyponatremia and water intoxication. In late pregnancy and postpartum, monitor for uterine contractions due to possible vasopressin activity. Fetal monitoring should include heart rate and growth if prolonged use. |
| Fertility Effects | In clinical studies, desmopressin has not been shown to impair fertility. No adverse effects on reproductive function in males or females have been reported. However, any hormone imbalance from underlying condition (e.g., diabetes insipidus) may affect fertility. |